OBJECTIVE: To examine the relationship between subclinical diabetic macular edema (DME) and the development of clinically significant macular edema (CSME) in nonproliferative diabetic retinopathy (NPDR) in patients with type 2 diabetes. METHODS: A prospective, monocenter, observational study was designed to follow patients/eyes with type 2 diabetes and NPDR (Early Treatment Diabetic Retinopathy Study levels 20 and 35) with no prior laser treatment for 2 years or until development of CSME. Ophthalmologic examinations, including best-corrected visual acuity, fundus photography and optical coherence tomography (OCT), were performed at baseline, 6 months and a final visit. RESULTS: A total of 348 patients completed study follow-up; 26 eyes developed CSME. Six out of 32 eyes/patients presenting subclinical DME at baseline developed CSME (18.7%), while 20 out of 316 eyes without subclinical DME developed CSME (6.3%). Eyes/patients with subclinical DME presented a risk for DME progression 3.686 times higher than that of eyes/patients without subclinical DME (95% confidence interval 1.221-7.988). CONCLUSIONS: Subclinical DME in eyes with NPDR identified by center point thickness measured on a Stratus OCT is a good predictor of CSME development.
OBJECTIVE: To examine the relationship between subclinical diabetic macular edema (DME) and the development of clinically significant macular edema (CSME) in nonproliferative diabetic retinopathy (NPDR) in patients with type 2 diabetes. METHODS: A prospective, monocenter, observational study was designed to follow patients/eyes with type 2 diabetes and NPDR (Early Treatment Diabetic Retinopathy Study levels 20 and 35) with no prior laser treatment for 2 years or until development of CSME. Ophthalmologic examinations, including best-corrected visual acuity, fundus photography and optical coherence tomography (OCT), were performed at baseline, 6 months and a final visit. RESULTS: A total of 348 patients completed study follow-up; 26 eyes developed CSME. Six out of 32 eyes/patients presenting subclinical DME at baseline developed CSME (18.7%), while 20 out of 316 eyes without subclinical DME developed CSME (6.3%). Eyes/patients with subclinical DME presented a risk for DME progression 3.686 times higher than that of eyes/patients without subclinical DME (95% confidence interval 1.221-7.988). CONCLUSIONS: Subclinical DME in eyes with NPDR identified by center point thickness measured on a Stratus OCT is a good predictor of CSME development.
Authors: Haiying Chen; Mei Hong Tan; Dustin Pomerleau; Elaine W Chong; Lyndell L Lim; R C Andrew Symons Journal: Graefes Arch Clin Exp Ophthalmol Date: 2019-12-26 Impact factor: 3.117
Authors: Cristina Hernández; Massimo Porta; Francesco Bandello; Jakob Grauslund; Simon P Harding; Stephen J Aldington; Catherine Egan; Ulrik Frydkjaer-Olsen; José García-Arumí; Jonathan Gibson; Gabriele E Lang; Rosangela Lattanzio; Pascale Massin; Edoardo Midena; Berta Ponsati; Luísa Ribeiro; Peter Scanlon; José Cunha-Vaz; Rafael Simó Journal: J Clin Med Date: 2020-04-24 Impact factor: 4.241
Authors: Ines P Marques; Maria H Madeira; Ana L Messias; Torcato Santos; António C-V Martinho; João Figueira; José Cunha-Vaz Journal: J Clin Med Date: 2020-05-12 Impact factor: 4.241